LTI pursues niche, orphan drug indications in lung injury and disease for which there is no effective therapeutic option. LTI’s first product, LTI-01 for pleural disease, has received more than $12 million dollars in NIH funding for development and IND-enabling studies, and it targets a global market worth over $1B.